Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...
5d
GlobalData on MSNEC approves CSL’s Andembry to stop hereditary angioedema attacksCSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
If approved, sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and ...
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
Pharmaceuticals announced that Infarmed in Portugal has recommended ORLADEYO for the routine prevention of recurrent attacks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results